Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 3/20 | 0.39 |
| ▸ | PIM3 | Q86V86 | 3/20 | 0.39 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 7/20 | 0.37 |
| ▸ | GUSB | P08236 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | RARA | P10276 | 1/20 | 0.33 |
| ▸ | RARB | P10826 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1107948 | 0.94 | PIM1 (0.41) | PIM1PIM3PIM2PDK2GUSB | |
| SCHEMBL1107911 | 0.92 | GUSB (0.36) | PIM1PIM3PIM2PDK2GUSB | |
| SCHEMBL1107936 | 0.92 | GUSB (0.41) | PIM1PIM3PIM2PDK2GUSB | |
| SCHEMBL1107935 | 0.92 | GUSB (0.38) | PIM1PIM3PIM2PDK2GUSB | |
| SCHEMBL1107977 | 0.92 | PDK2 (0.39) | PIM1PIM3PIM2PDK2GUSB | |
| SCHEMBL1107869 | 0.88 | PIM1 (0.46) | PIM1PIM3PIM2MEN1RAB9A | |
| SCHEMBL1107964 | 0.88 | PDK2 (0.34) | PIM1PIM3PIM2PDK2GUSB | |
| SCHEMBL1107952 | 0.87 | GUSB (0.40) | PIM1PIM3PIM2PDK2GUSB | |
| SCHEMBL1107971 | 0.86 | PDK2 (0.35) | PIM1PIM3PIM2PDK2GUSB | |
| SCHEMBL1107955 | 0.85 | PIM1 (0.36) | PIM1PIM3PIM2PDK2GUSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153277-B2 | Compound having thiadiazole ring structure substituted with pyridyl group and organic electroluminescent device | HODOGAYA CHEMICAL CO., LTD. (JP) | 2012-04-10 | — | — | US | disclosed |
| US-8153277-B2 | Compound having thiadiazole ring structure substituted with pyridyl group and organic electroluminescent device | HODOGAYA CHEMICAL CO., LTD. (JP) | 2012-04-10 | — | — | US | disclosed |
| US-20090108750-A1 | COMPOUND HAVING THIADIAZOLE RING STRUCTURE SUBSTITUTED WITH PYRIDYL GROUP AND ORGANIC ELECTROLUMINESCENT DEVICE | HODOGAYA CHEMICAL CO., LTD. (JP) | 2009-04-30 | — | — | US | disclosed |
| US-20090108750-A1 | COMPOUND HAVING THIADIAZOLE RING STRUCTURE SUBSTITUTED WITH PYRIDYL GROUP AND ORGANIC ELECTROLUMINESCENT DEVICE | HODOGAYA CHEMICAL CO., LTD. (JP) | 2009-04-30 | — | — | US | disclosed |
| EP-2009013-A1 | COMPOUND HAVING THIADIAZOLE RING STRUCTURE SUBSTITUTED WITH PYRIDYL GROUP AND ORGANIC ELECTROLUMINESCENT DEVICE | Hodogaya Chemical Co., Ltd. (JP) | 2008-12-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090108750-A1 | COMPOUND HAVING THIADIAZOLE RING STRUCTURE SUBSTITUTED WITH PYRIDYL GROUP AND ORGANIC ELECTROLUMINESCENT DEVICE | OXA1L, SLCO4C1, SLCO2B1 | PIM1 1477/4885PIM3 1919/4885PIM2 1487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.